$JAGX RALLY ON REFINANCING OF DEBT AGREEMENT

********HOT STOCK FOR THE DAYS TO COME ON THE BACK OF NEW DEBT REFINANCING AGREEMENT ANNOUNCED MONDAY. RALLY STALLED WITH THE MARKET BUT SHOULD SEE GREATER GAINS IN THE DAYS TO COME. BREAK ABOVE THE 50MA AND MACD CROSS NICE SIGNALS FOR A LONG.

COMPANY PROFILE
Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.